Последно актуализиране :
08/05/2024
противораково лекарство   Dacarbazine  
Инжекция/Инжекционен
Стабилност на разтвори Стабилност на смеси Фактори, повлияващи стабилността Съвместимост Път на въвеждане Библиография Pdf
   Химична структура  

Търговско наименование   Търговско наименование     

Търговските имена са примерни и съставът на помощните вещества може да бъде различен в зависимост от държавата и лабораториите

Acocarb Мексико
Celdaz Индия, Перу
Dabaz Индия
Dacarb Индия, Перу
Dacarba Индия
Dacarbaz Турция
Dacarbazin Австрия, Малайзия, Полша, Унгария
Dacarbazina Аржентина, Еквадор, Испания, Колумбия, Чили
Dacarbazine Австралия, Белгия, Великобритания, Дания, Индия, Иран, Ирландия, Канада, нова Зеландия, Съединени Американски щати / САЩ, Швеция
Dacarex Индия, Перу
Dacarin Индия
Dacarpalm Перу
Dacarzine Индия
Dacatic Финландия
Dacin Швейцария
Dacmed Индия
Daracina Колумбия
Deticene Гърция, Италия, Саудитска Арабия, Тунис, Франция, Холандия
Detilem Мексико
Detimedac Германия, Колумбия
DTI Малайзия
DTIC Австралия, Австрия, Великобритания, нова Зеландия, Съединени Американски щати / САЩ, Швеция
Fauldetic Португалия
Ifadac Мексико
Oncocarbil Аржентина, Еквадор, Перу
Tiferomed Мексико
Библиография   Инжекция/Инжекционен   Библиография : Dacarbazine  
Вид Публикация
3 Списание Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26 Списание Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL.
Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
Am J Health-Syst Pharm 1997 ; 54: 915-920.
40 Списание Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC.
Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags.
Pharm Sci Communications 1994 ; 4: 97-101.
57 Списание Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 Списание Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Списание Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Списание Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Списание Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
184 Списание Stewart JT, Warren FW, King DT, Fox JL.
Stability of ondansetron hydrochloride and five antineoplasic medications.
Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244 Списание Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 Списание Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Списание Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Списание Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307 Списание Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Списание Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Списание Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
353 Списание Lunn G, Sansone EB.
Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid.
Am J Hosp Pharm 1987 ; 44: 2519-2524.
492 Списание Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
860 Списание Nelson RW, Young R, Lamnin M.
Visual incompatibility of dacarbazine and heparin.
Am J Hosp Pharm 1987 ; 44: 2028.
905 Списание Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1383 Списание Stevens MFG, Peatey L.
Photodegradation of solutions of the antitumour drug DTIC.
J Pharm Pharmacol 1978 ; 30: 47P.
1410 Списание Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1501 Списание Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1635 Списание El Aatmani M, Poujol S, Astre C, Malosse F, Pinguet F.
Stability of dacarbazine in amber glass vials and polyvinyl chloride bags.
Am J Health-Syst Pharm 2002 ; 59: 1351-1356.
2107 Списание Trissel LA, Zhang Y, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration.
Int J Pharm Compound 2006 ; 10: 234-236.
3266 Лаборатория Lipomed Laboratories
Dacarbazine solutions: In Use stability of dacarbazine lipomed®
Lipomed 2011
3267 Лаборатория Lipomed Laboratories
Dacarbazine Lipomed - Summary of Product Characteristics
Lipomed 2011
3540 Лаборатория Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3605 Лаборатория Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit
Lipomed 2010

  Mentions Légales